RxDoctor Payments Data

Daniel Holt, MD

Family Medicine · Washington, PANPI 1922003375

Payments from drug & device makers

$29,690in general payments, 2019–2025

Across 423 payments — averaging $70.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$19K
  • Shire North American Group Inc$5K
  • Novo Nordisk$635
  • AbbVie$548
  • Lilly USA, LLC$509
  • Pfizer$466
  • plus $3K from 45 others

What the payments were for

  • Consulting fees$6,99024%
  • Speaking & faculty fees$15,63153%
  • Travel & lodging$3271%
  • Food & beverage$6,74223%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,690 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,788
Medicare patients
58
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlassiaAlpha-1-Proteinase Inhibitor100$1,312,941
Aralast NpAlpha-1-Proteinase Inhibitor32$299,707
TrulicityDulaglutide88$112,923
OzempicSemaglutide90$98,155
EliquisApixaban106$79,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$51,341
JardianceEmpagliflozin32$37,909
JanuviaSitagliptin Phosphate21$33,543
MounjaroTirzepatide22$22,603
TradjentaLinagliptin24$16,469
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$15,511
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,276
XareltoRivaroxaban13$11,233
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$11,221
Rufinamide13$10,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Glassia$18,985$1,312,941100 claims
Lilly USA, LLCTrulicity, Mounjaro$509$135,525110 claims
Novo NordiskOzempic$635$98,15590 claims
PfizerEliquis, Prempro$466$81,906117 claims
GSKTrelegy Ellipta, Anoro Ellipta$330$62,61797 claims
Boehringer IngelheimJardiance, Tradjenta$104$54,37856 claims
MerckJanuvia$76$33,54321 claims
Johnson & JohnsonXarelto$28$11,23313 claims
AstraZenecaFarxiga$161$10,45616 claims
NovartisEntresto$89$7,61312 claims
Sanofi-aventis U.S. LLCLantus$15$3,23114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Washington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →